A new information-sharing agreement between the SEC and the Food and Drug Administration (FDA) is expected to increase regulatory scrutiny of publicly traded life sciences companies.
The memorandum of understanding (MOU), announced on August 31, establishes a formal framework for the agencies to exchange nonpublic information related to FDA-regulated products,
The